Crescendo Bioscience is conducting its prospective outcomes study

Vectra® DA Guided Care Compared with Usual Care, for RA patients with inadequate response to methotrexate. If you would like more information or would like to participate in the study, please click here for more information.

Please contact us at

Vectra DA was validated through a rigorous development process

The Vectra DA test was developed using a broad survey of RA biology, with serial studies to determine a final assay composed of biomarkers that robustly assess disease activity. Hundreds of candidate biomarkers were evaluated, involving over 1,900 serum samples from more than 1,700 patients, to arrive at the 12 biomarkers in Vectra DA.



View All Publications

A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure.

Reanalysis of the multi-biomarker disease activity score for assessing disease activity in the AMPLEstudy: Comment on the article by Fleischmann et al.

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice

©2019 Crescendo Bioscience, Inc. All rights reserved. Vectra, Crescendo Bioscience, MyRA and the associated logos are trademarks or registered trademarks of Crescendo Bioscience, Inc. in the United States and other jurisdictions.